Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.

ABSTRACT:

Purpose

The aim of this study was to compare fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed tomography (CE-CT) for the prediction of progression-free survival (PFS) and disease-specific survival (DSS) in patients with stage IV breast cancer undergoing systemic therapy.

Methods

Sixty-five patients with metastatic breast cancer treated with first- or second-line systemic therapy in prospective clinical trials were included. Response to treatment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for CE-CT and by PET Response Criteria in Solid Tumors (PERCIST), respectively.

Results

All responders by RECIST (n = 22) were also responders by PERCIST, but 40% (17/43) of non-responders b

SUBMITTER: Riedl CC 

PROVIDER: S-EPMC5526620 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature